I

Intercept Pharmaceuticals Inc
F:I4P

Watchlist Manager
Intercept Pharmaceuticals Inc
F:I4P
Watchlist
Price: 17.52 EUR
Market Cap: €732.8m

Net Margin

-22.8%
Current
Declining
by 76.1%
vs 3-y average of 53.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-22.8%
=
Net Income
$-61.6m
/
Revenue
$317.7m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-22.8%
=
Net Income
€-61.6m
/
Revenue
$317.7m

Peer Comparison

Country Company Market Cap Net
Margin
US
Intercept Pharmaceuticals Inc
F:I4P
732.5m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.3B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 76% of companies in the United States of America
Percentile
24th
Based on 15 072 companies
24th percentile
-22.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Intercept Pharmaceuticals Inc
Glance View

Market Cap
732.8m EUR
Industry
Biotechnology

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 437 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. The Company’s other compounds are in early stages of research and development pipeline, including INT-787 compound, an FXR agonist is in a Phase I clinical trial.

I4P Intrinsic Value
Not Available
I
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-22.8%
=
Net Income
$-61.6m
/
Revenue
$317.7m
What is Intercept Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Intercept Pharmaceuticals Inc is -22.8%, which is below its 3-year median of 53.3%.

How has Net Margin changed over time?

Over the last 3 years, Intercept Pharmaceuticals Inc’s Net Margin has increased from -125% to -22.8%. During this period, it reached a low of -125% on Aug 30, 2020 and a high of 83.1% on Dec 31, 2022.

Back to Top